UBE2S interacting with TRIM28 in the nucleus accelerates cell cycle by ubiquitination of p27 to promote hepatocellular carcinoma development

Ren-Yu Zhang,Ze-Kun Liu,Ding Wei,Yu-Le Yong,Peng Lin,Hao Li,Man Liu,Nai-Shan Zheng,Ke Liu,Cai-Xia Hu,Xiao-Zhen Yang,Zhi-Nan Chen,Huijie Bian
DOI: https://doi.org/10.1038/s41392-020-00432-z
IF: 39.3
2021-02-16
Signal Transduction and Targeted Therapy
Abstract:Abstract Genomic sequencing analysis of tumors provides potential molecular therapeutic targets for precision medicine. However, identifying a key driver gene or mutation that can be used for hepatocellular carcinoma (HCC) treatment remains difficult. Here, we performed whole-exome sequencing on genomic DNA obtained from six pairs of HCC and adjacent tissues and identified two novel somatic mutations of UBE2S (p. Gly57Ala and p. Lys63Asn). Predictions of the functional effects of the mutations showed that two amino-acid substitutions were potentially deleterious. Further, we observed that wild-type UBE2S, especially in the nucleus, was significantly higher in HCC tissues than that in adjacent tissues and closely related to the clinicopathological features of patients with HCC. Functional assays revealed that overexpression of UBE2S promoted the proliferation, invasion, metastasis, and G1/S phase transition of HCC cells in vitro, and promoted the tumor growth significantly in vivo. Mechanistically, UBE2S interacted with TRIM28 in the nucleus, both together enhanced the ubiquitination of p27 to facilitate its degradation and cell cycle progression. Most importantly, the small-molecule cephalomannine was found by a luciferase-based sensitive high-throughput screen (HTS) to inhibit UBE2S expression and significantly attenuate HCC progression in vitro and in vivo, which may represent a promising strategy for HCC therapy.
biochemistry & molecular biology,cell biology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to identify the driver genes or mutations that play a key role in hepatocellular carcinoma (HCC) and explore how these genes participate in cell - cycle progression, thereby promoting the development of HCC. Specifically, the researchers discovered two new somatic mutations in the UBE2S gene (p. Gly57Ala and p. Lys63Asn) through whole - exome sequencing (WES), and further research revealed that the expression of wild - type UBE2S in HCC tissues was significantly increased, especially in the nucleus, and was closely related to the clinicopathological features of patients. In addition, the study also explored how UBE2S accelerates the cell cycle and promotes the development of HCC by interacting with TRIM28, and discovered a small - molecule compound - Cephalomannine, which can inhibit the expression of UBE2S and significantly slow down the progression of HCC. The key points of the paper include: - **New mutations in UBE2S**: Two new somatic mutations in UBE2S were first identified through WES technology. - **High expression of UBE2S**: It was confirmed that the high expression of wild - type UBE2S in HCC tissues, especially in the nucleus, was associated with poor prognosis in patients. - **Function of UBE2S**: Research shows that UBE2S promotes the degradation of p27 by enhancing its ubiquitination through interacting with TRIM28, thereby accelerating cell - cycle progression and promoting the development of HCC. - **Treatment strategy**: High - throughput screening found that Cephalomannine can significantly inhibit the expression of UBE2S and reduce the growth of HCC, providing a new potential strategy for the treatment of HCC. These findings not only deepen the understanding of the pathogenesis of HCC, but also provide a theoretical basis for the development of new treatment methods for HCC.